NCT01831115

Brief Summary

To improve the diagnostic and prognostic utility of various biomarkers, detailed patient's history, physical examinations and technical devices in patients presenting with acute dyspnea.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5,452

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2006

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2006

Completed
7 years until next milestone

First Submitted

Initial submission to the registry

April 4, 2013

Completed
11 days until next milestone

First Posted

Study publicly available on registry

April 15, 2013

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
10.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

February 28, 2025

Status Verified

February 1, 2025

Enrollment Period

9.3 years

First QC Date

April 4, 2013

Last Update Submit

February 25, 2025

Conditions

Dyspnea

Keywords

heart failureBNPacute dyspnoea

Outcome Measures

Primary Outcomes (3)

  • Diagnostic accuracy for the diagnosis of heart failure

    Diagnostic of various biomarkers (such as natriuretic peptides, cardiac troponins, microRNA...), physical examination, detailed patient's history and novel technical devices.

    baseline

  • Prognostic utility in patients with dyspnea

    Prognostic value of various biomarkers, echocardiography data and novel technical measurements regarding rehospitalisation, cardiovascular mortality and all-cause and mortality

    360 days

  • Prognostic utility in patients with dyspnea

    Prognostic value of various biomarkers, echocardiography data and novel technical measurements regarding rehospitalisation, cardiovascular mortality and all-cause and mortality

    720 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients presenting with acute dyspnea to the emergency department.

You may qualify if:

  • chief complaint of dyspnea (not penetrating injury or trauma related)
  • subjects must be at least 18 years of age

You may not qualify if:

  • patient is unable or unwilling to give informed consent
  • patient on hemodialysis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

University Hospital Basel

Basel, 4031, Switzerland

Location

University Hospital Zurich

Zurich, 8091, Switzerland

Location

Related Publications (8)

  • Belkin M, Wussler DN, Shrestha S, Lopez-Ayala P, Nowak A, Michou E, Papachristou A, Popescu C, Strebel I, Kozhuharov N, Sabti Z, Netzer I, Zimmermann T, Diebold M, Breidthardt T, Mueller C. Prognostic value of health-related quality of life in patients with acute dyspnoea: a cohort study. Swiss Med Wkly. 2025 Apr 15;155:3785. doi: 10.57187/s.3785.

    PMID: 40450733DERIVED

  • Belkin M, Wussler D, Michou E, Strebel I, Kozhuharov N, Sabti Z, Nowak A, Shrestha S, Lopez-Ayala P, Prepoudis A, Stefanelli S, Schafer I, Mork C, Albus M, Danier I, Simmen C, Zimmermann T, Diebold M, Breidthardt T, Mueller C. Prognostic Value of Self-Reported Subjective Exercise Capacity in Patients With Acute Dyspnea. JACC Adv. 2023 May 26;2(3):100342. doi: 10.1016/j.jacadv.2023.100342. eCollection 2023 May.

    PMID: 38939580DERIVED

  • Breidthardt T, van Doorn WPTM, van der Linden N, Diebold M, Wussler D, Danier I, Zimmermann T, Shrestha S, Kozhuharov N, Belkin M, Porta C, Strebel I, Michou E, Gualandro DM, Nowak A, Meex SJR, Mueller C. Diurnal Variations in Natriuretic Peptide Levels: Clinical Implications for the Diagnosis of Acute Heart Failure. Circ Heart Fail. 2022 Jun;15(6):e009165. doi: 10.1161/CIRCHEARTFAILURE.121.009165. Epub 2022 Jun 7.

    PMID: 35670217DERIVED

  • Diebold M, Kozhuharov N, Wussler D, Strebel I, Sabti Z, Flores D, Shrestha S, Martin J, Staub D, Venge P, Mueller C, Breidthardt T. Mortality and pathophysiology of acute kidney injury according to time of occurrence in acute heart failure. ESC Heart Fail. 2020 Oct;7(5):3219-3224. doi: 10.1002/ehf2.12788. Epub 2020 Jun 24.

    PMID: 32578962DERIVED

  • Wussler D, Kozhuharov N, Tavares Oliveira M, Bossa A, Sabti Z, Nowak A, Murray K, du Fay de Lavallaz J, Badertscher P, Twerenbold R, Shrestha S, Flores D, Nestelberger T, Walter J, Boeddinghaus J, Zimmermann T, Koechlin L, von Eckardstein A, Breidthardt T, Mueller C. Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia. Clin Chem. 2019 Dec;65(12):1532-1542. doi: 10.1373/clinchem.2019.306787. Epub 2019 Oct 15.

    PMID: 31615771DERIVED

  • Wussler D, Kozhuharov N, Sabti Z, Walter J, Strebel I, Scholl L, Miro O, Rossello X, Martin-Sanchez FJ, Pocock SJ, Nowak A, Badertscher P, Twerenbold R, Wildi K, Puelacher C, du Fay de Lavallaz J, Shrestha S, Strauch O, Flores D, Nestelberger T, Boeddinghaus J, Schumacher C, Goudev A, Pfister O, Breidthardt T, Mueller C. External Validation of the MEESSI Acute Heart Failure Risk Score: A Cohort Study. Ann Intern Med. 2019 Feb 19;170(4):248-256. doi: 10.7326/M18-1967. Epub 2019 Jan 29.

    PMID: 30690646DERIVED

  • Badertscher P, Strebel I, Honegger U, Schaerli N, Mueller D, Puelacher C, Wagener M, Abacherli R, Walter J, Sabti Z, Sazgary L, Marbot S, du Fay de Lavallaz J, Twerenbold R, Boeddinghaus J, Nestelberger T, Kozhuharov N, Breidthardt T, Shrestha S, Flores D, Schumacher C, Wild D, Osswald S, Zellweger MJ, Mueller C, Reichlin T. Automatically computed ECG algorithm for the quantification of myocardial scar and the prediction of mortality. Clin Res Cardiol. 2018 Sep;107(9):824-835. doi: 10.1007/s00392-018-1253-z. Epub 2018 Apr 17.

    PMID: 29667014DERIVED

  • Breidthardt T, Moreno-Weidmann Z, Uthoff H, Sabti Z, Aeppli S, Puelacher C, Stallone F, Twerenbold R, Wildi K, Kozhuharov N, Wussler D, Flores D, Shrestha S, Badertscher P, Boeddinghaus J, Nestelberger T, Gimenez MR, Staub D, Aschwanden M, Lohrmann J, Pfister O, Osswald S, Mueller C. How accurate is clinical assessment of neck veins in the estimation of central venous pressure in acute heart failure? Insights from a prospective study. Eur J Heart Fail. 2018 Jul;20(7):1160-1162. doi: 10.1002/ejhf.1111. Epub 2018 Jan 4. No abstract available.

    PMID: 29314487DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

EDTA, Plasma and Urine

MeSH Terms

Conditions

DyspneaHeart Failure

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsHeart DiseasesCardiovascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2013

First Posted

April 15, 2013

Study Start

April 1, 2006

Primary Completion

August 1, 2015

Study Completion

December 1, 2025

Last Updated

February 28, 2025

Record last verified: 2025-02

Locations

CH(2)